Laboratory Medicine ›› 2026, Vol. 41 ›› Issue (3): 282-286.DOI: 10.3969/j.issn.1673-8640.2026.03.012
Previous Articles Next Articles
Received:2024-11-05
Revised:2025-09-24
Online:2026-03-30
Published:2026-04-14
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2026.03.012
| 引物名称 | 正向引物（5'~3'） | 反向引物（5'~3'） | 产物长度/ bp |
|---|---|---|---|
| 23S rRNA | ACGGCGGCCGTAACTATA | TCAAGCTGGTTAGCTA | 300 |
| ermB | TCTGGTTGTCATTGAAGCCT | TAGGGACCTCTTTAGCTCCT | 1 400 |
| 引物名称 | 正向引物（5'~3'） | 反向引物（5'~3'） | 产物长度/ bp |
|---|---|---|---|
| 23S rRNA | ACGGCGGCCGTAACTATA | TCAAGCTGGTTAGCTA | 300 |
| ermB | TCTGGTTGTCATTGAAGCCT | TAGGGACCTCTTTAGCTCCT | 1 400 |
| 项目 | 相关抗菌药物 | 耐药机制 |
|---|---|---|
| 230216 | ||
| OXA-489 | 青霉烷 | 抗菌药物灭活 |
| tet（O/M/O） | 四环素类 | 抗菌药物靶点保护 |
| gyrA | 氟喹诺酮类 | 抗菌药物靶点改变 |
| RE-cmeB | 大环内酯类、氟喹诺酮类、头孢菌素、夫西地烷 | 抗菌药物外排 |
| APH（3'）-Ⅲa | 氨基糖苷类 | 抗菌药物灭活 |
| ANT（6）-Ⅰa | 氨基糖苷类 | 抗菌药物灭活 |
| 231031 | ||
| qacG | 消毒剂和防腐剂 | 抗菌药物外排 |
| tet（L） | 四环素类 | 抗菌药物外排 |
| fexA | 苯酚抗菌药物 | 抗菌药物外排 |
| gyrA | 氟喹诺酮类 | 抗菌药物靶点改变 |
| adeF | 氟喹诺酮类、四环素类 | 抗菌药物外排 |
| RE-cmeB | 大环内酯类、氟喹诺酮类、头孢菌素、夫西地烷 | 抗菌药物外排 |
| OXA-455 | 青霉烷 | 抗菌药物灭活 |
| oprZ | 大环内酯类、氟喹诺酮类、氨基糖苷类、头孢菌素 | 抗菌药物外排 |
| Limosilactobacillus reuteri cat-TC | 苯酚抗菌药物 | 抗菌药物灭活 |
| 项目 | 相关抗菌药物 | 耐药机制 |
|---|---|---|
| 230216 | ||
| OXA-489 | 青霉烷 | 抗菌药物灭活 |
| tet（O/M/O） | 四环素类 | 抗菌药物靶点保护 |
| gyrA | 氟喹诺酮类 | 抗菌药物靶点改变 |
| RE-cmeB | 大环内酯类、氟喹诺酮类、头孢菌素、夫西地烷 | 抗菌药物外排 |
| APH（3'）-Ⅲa | 氨基糖苷类 | 抗菌药物灭活 |
| ANT（6）-Ⅰa | 氨基糖苷类 | 抗菌药物灭活 |
| 231031 | ||
| qacG | 消毒剂和防腐剂 | 抗菌药物外排 |
| tet（L） | 四环素类 | 抗菌药物外排 |
| fexA | 苯酚抗菌药物 | 抗菌药物外排 |
| gyrA | 氟喹诺酮类 | 抗菌药物靶点改变 |
| adeF | 氟喹诺酮类、四环素类 | 抗菌药物外排 |
| RE-cmeB | 大环内酯类、氟喹诺酮类、头孢菌素、夫西地烷 | 抗菌药物外排 |
| OXA-455 | 青霉烷 | 抗菌药物灭活 |
| oprZ | 大环内酯类、氟喹诺酮类、氨基糖苷类、头孢菌素 | 抗菌药物外排 |
| Limosilactobacillus reuteri cat-TC | 苯酚抗菌药物 | 抗菌药物灭活 |
| [1] | LIU F, LEE S A, XUE J, et al. Global epidemiology of campylobacteriosis and the impact of COVID-19[J]. Front Cell Infect Microbiol, 2022, 12:979055. |
| [2] |
TIKHOMIROVA A, MCNABB E R, PETTERLIN L, et al. Campylobacter jejuni virulence factors:update on emerging issues and trends[J]. J Biomed Sci, 2024, 31(1):45.
DOI |
| [3] |
FINSTERER J. Triggers of Guillain-Barré syndrome:Campylobacter jejuni predominates[J]. Int J Mol Sci, 2022, 23(22):14222.
DOI URL |
| [4] | ZHANG D T, ZHANG X, LYU B, et al. Genomic analysis and antimicrobial resistance of Campylobacter jejuni isolated from diarrheal patients-Beijing municipality, China,2019-2021[J]. China CDC Wkly, 2023, 5(19):424-433. |
| [5] | GAO F, TU L, CHEN M, et al. Erythromycin resistance of clinical Campylobacter jejuni and Campylobacter coli in Shanghai,China[J]. Front Microbiol, 2023, 14:1145581. |
| [6] | BOLINGER H, KATHARIOU S. The current state of macrolide resistance in Campylobacter spp.:trends and impacts of resistance mechanisms[J]. Appl Environ Microbiol, 2017, 83(12):e00416-e00417. |
| [7] | QIN S, WANG Y, ZHANG Q, et al. Report of ribosomal RNA methylase gene erm(B)in multidrug-resistant Campylobacter coli[J]. J Antimicrob Chemother, 2014, 69(4):964-968. |
| [8] |
NOR AMDAN N A, SHAHRULZAMRI N A, HASHIM R, et al. Understanding the evolution of macrolides resistance:a mini review[J]. J Glob Antimicrob Resist, 2024, 38:368-375.
DOI URL |
| [9] | WIECZOREK K, OSEK J. Antimicrobial resistance mechanisms among Campylobacter[J]. Biomed Res Int, 2013, 2013:340605. |
| [10] |
GIBREEL A, KOS V N, KEELAN M, et al. Macrolide resistance in Campylobacter jejuni and Campylobacter coli:molecular mechanism and stability of the resistance phenotype[J]. Antimicrob Agents Chemother, 2005, 49(7):2753-2759.
DOI URL |
| [11] |
CHENG Y, ZHANG W, LU Q, et al. Point deletion or insertion in CmeR-Box,A2075G substitution in 23S rRNA,and presence of erm(B)are key factors of erythromycin resistance in Campylobacter jejuni and Campylobacter coli isolated from central China[J]. Front Microbiol, 2020, 11:203.
DOI URL |
| [12] | 赵顺英, 钱素云, 陈志敏, 等. 儿童肺炎支原体肺炎诊疗指南(2023年版)[J]. 新发传染病电子杂志, 2024, 9(1):73-79. |
| [13] |
LIN J, MICHEL L O, ZHANG Q. CmeABC functions as a multidrug efflux system in Campylobacter jejuni[J]. Antimicrob Agents Chemother, 2002, 46(7):2124-2131.
DOI URL |
| [14] |
GIBREEL A, TAYLOR D E. Macrolide resistance in Campylobacter jejuni and Campylobacter coli[J]. J Antimicrob Chemother, 2006, 58(2):243-255.
DOI URL |
| [15] | YAO H, SHEN Z, WANG Y, et al. Emergence of a potent multidrug efflux pump variant that enhances Campylobacter resistance to multiple antibiotics[J]. mBio, 2016, 7(5):e01543-16. |
| [16] |
SHEPPARD S K, MAIDEN M C. The evolution of Campylobacter jejuni and Campylobacter coli[J]. Cold Spring Harb Perspect Biol, 2015, 7(8):a018119.
DOI URL |
| [1] | . [J]. Laboratory Medicine, 2026, 41(2): 193-195. |
| [2] | LI Li, DU Jinye, WANG Xinyi, DAI Jing. Risk factors，drug resistance and virulence analysis of Klebsiella pneumoniae bloodstream infection [J]. Laboratory Medicine, 2025, 40(9): 885-891. |
| [3] | . [J]. Laboratory Medicine, 2025, 40(9): 907-913. |
| [4] | WU Xiaoqiong, CHEN Dongmiao, LIANG Yumin, WANG Congrong. Influence of Helicobacter pylori Ⅰ and Ⅱ infection on chronic gastritis [J]. Laboratory Medicine, 2025, 40(8): 798-803. |
| [5] | WANG Yali, CHEN Zongyao, ZHENG Mao, XU Dan, GUO Jiniuniu. Clinical characteristics and prognostic factors of patients with carbapenem-resistant hypervirulent Klebsiella pneumoniae infection [J]. Laboratory Medicine, 2025, 40(7): 693-697. |
| [6] | . [J]. Laboratory Medicine, 2025, 40(5): 508-511. |
| [7] | . [J]. Laboratory Medicine, 2025, 40(1): 102-104. |
| [8] | GUO Chaonan, WANG Yanyan, ZHANG Bei, PANG Jingying, CUI Feifei, ZHAO Yongxin, SU Bing. Analysis of drug resistance and virulence of Klebsiella pneumoniae from different clinical samples [J]. Laboratory Medicine, 2024, 39(9): 880-887. |
| [9] | CAI Min, ZHANG Hui. Research progress for CRE infection in intensive care unit patients [J]. Laboratory Medicine, 2024, 39(9): 913-918. |
| [10] | HUANG Linling, XU Meirong, SHEN Xiaowen, GU LingLi, SHEN Hongmei. Changes and significance of autophagy in peripheral blood lymphocytes of patients with carbapenem-resistant Enterobacteriaceae-bloodstream infection [J]. Laboratory Medicine, 2024, 39(8): 759-763. |
| [11] | WU Xinzhe, MAO Haifeng, YANG Jin, ZUO Chunlei, JIN Danting. Clinical application of MALDI-TOF direct droplet culture method in rapid determination of CRKP [J]. Laboratory Medicine, 2024, 39(6): 587-591. |
| [12] | SUN Miaoli, WU Qiong, WANG Yingzhi, WANG Jianqiang, GAO Feng, TANG Jin. Research progress on determination and treatment of carbapenem-resistant Klebsiella pneumoniae [J]. Laboratory Medicine, 2024, 39(6): 615-620. |
| [13] | LI Yumei, LONG Xiaoping, MAO Xiaoxue, HU Xiaoying, GU Chenghong. Correlation between microbiological characteristics of Helicobacter pylori and chronic atrophic gastritis [J]. Laboratory Medicine, 2024, 39(5): 497-503. |
| [14] | YU Feng, HU Longhua, XIAO Yanping, YANG Junping. Virulence genes and molecular characteristics of Klebsiella pneumoniae isolated from bloodstream infection patients [J]. Laboratory Medicine, 2024, 39(3): 249-255. |
| [15] | . [J]. Laboratory Medicine, 2024, 39(3): 298-301. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
